TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Study to Evaluate the Role of PlasmaJet in Patients Undergoing Groin Node Dissection for Vulval Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* To be included in this study, all women should undergo BGND during their treatment pathway for histologically confirmed vulval cancer.~* Participant is willing and able to provide informed consent.~* Aged 18 years or above.~* Participant willing to allow General Practitioner and other health care professionals, if appropriate, to be notified of participation in study.~Exclusion Criteria:~* Women with vulval cancer who do not undergo BGND.~* Women with any previous groin surgery~* Women with any previous radiotherapy to the pelvic area including the groins~* Patient choice~* Women who are pregnant, lactating or planning pregnancy during the course of the study

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Surgery without trial (PJ) device (Type: NO_INTERVENTION): All steps of surgery are conducted as per standard practice in accordance with the current practice at the time. In all cases a bilateral inguino-femoral groin node dissection was performed, with en-bloc removal of the superficial and deep inguinal nodes with conservation of the long saphenous vein.
- Surgery with trial (PJ) device (Type: ACTIVE_COMPARATOR): Use of the PJ was limited to the randomised side only. All steps of surgery are conducted as per standard practice in accordance with the current practice at the time. In all cases a bilateral inguino-femoral groin node dissection was performed, with en-bloc removal of the superficial and deep inguinal nodes with conservation of the long saphenous vein. Haemostasis was ensured with diathermy and ties and just prior to wound closure, the surgeon used the PlasmaJet on the indicated groin to seal the lymph vessels and channels at a setting of 40% by spraying the argon plasma over the entire exposed surgical field at a distance of 10 mm from the surface to the tip of the instrument.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Cutting Balloon Versus Non-cutting Balloon for the Treatment of Venous Stenosis in the Fistulas of Hemodialyzed Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* The patient must have given his/her informed and signed consent~* The patient must be insured or beneficiary of a health insurance plan~* The patient is available for 12 months of follow-up~* The patient is on hemodialysis because of chronic renal insufficiency~* The patient's vascular access is an arterio-venous fistula~* The patient has a venous stenosis in the fistula (first event in the studied zone)~* The patient is scheduled for angioplasty~Exclusion Criteria:~* The patient is participating in another study~* The patient is in an exclusion period determined by a previous study~* The patient is under judicial protection, under tutorship or curatorship~* The patient refuses to sign the consent~* It is impossible to correctly inform the patient~* The patient cannot fluently read French~* The patient cannot understand French~* The patient is pregnant~* The patient is breastfeeding~* Short term dialysis~* The vascular access is a graft~* The stenosis in question is a recurrence, and not a first event in the studied zone~* The life expectancy of the patient is \< 12 months~* Medical emergency situation~* Peritoneal dialysis~* At-home dialysis

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Experimental arm (Type: EXPERIMENTAL): Patients in this arm will have angioplasty of a fistula stenosis using a cutting balloon
- Standard arm (Type: ACTIVE_COMPARATOR): Patients in this arm will have angioplasty of a fistula stenosis using a non-cutting balloon.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: To Evaluate the Safety and Efficacy of STSG-0002 Injection in Patients With Chronic Hepatitis B

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SEQUENTIAL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Patients with chronic HBV；~* Receiving anti-HB viral therapy;~* 10 IU/ml≤HBsAg≤3000 IU/ml.~Exclusion Criteria:~* Patients co-infected with hepatitis C virus, HIV, HAV, HDV, HEV;~* Liver cirrhosis;~* Hepatocellular carcinoma;~* Autoimmune liver disease;~* Clinical hepatic decompensation;~* Fibroscan\>12 kPa;~* a. hemoglobin\<110g/L（female）\<120 g/L（male），platelet\<ULN，white blood cell\<2.5×109/L；b. bilirubin\>1.5 ×ULN，ALT\>2 × ULN，serum albumin\<35 g/L；c. INR\>1.5；d. serum creatinine \>1.5×ULN.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- lowest dose treatment group (Type: EXPERIMENTAL): Subjects will receive one single lowest dose of STSG-0002 Injection following protocol requirements
- low dose treatment group (Type: EXPERIMENTAL): Subjects will receive one single low dose of STSG-0002 Injection following protocol requirements
- Intermediate dose treatment group (Type: EXPERIMENTAL): Subjects will receive one single intermediate dose of STSG-0002 Injection following protocol requirements
- A single high dose of treatment group (Type: EXPERIMENTAL): Subjects will receive one single high dose of STSG-0002 Injection following protocol requirements

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Transoral Robotic Surgery in Treating Patients With Benign or Stage I-IV Head and Neck Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Patients clinical, radiologic or pathologic evidence of a benign or malignant tumor in the oral cavity, oropharynx, nasopharynx, hypopharynx, larynx, retropharynx or parapharyngeal space~* Surgical access is amenable to treatment with conventional transoral surgical procedures~* ASA (American Society of Anesthesiologists) performance status (PS) of 1-4 or ECOG (Eastern Cooperative Oncology Group) PS 0-3, thereby including a population that stands to gain the most from a minimally invasive surgical approach~* Patients should have no serious acute infection~* Patients must sign a study-specific informed consent form~Exclusion Criteria:~* Evidence of distant metastases (below the clavicle) by clinical or radiographic measures~* ASA score \> 4; ECOG PS score \> 3~* Pregnancy (during first or 3rd trimester - due to risks of anesthesia)~* The presence of medical conditions which contraindicate general anesthesia~* Unexplained fever or untreated, active infection~* Inability to obtain exposure to allow performance of the planned transoral surgical procedure~* Proposed surgical site with history of prior treatment: radiation~* Tumor adherent to carotid artery or jugular vein~* Fixation to pre-vertebral tumor~* Mandibular invasion

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Arm I (Type: EXPERIMENTAL): Patients undergo transoral robotic microsurgery.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: Narcotics Inpatient / Outpatient

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* 18 years old or older~* Undergoing vaginal, laparoscopic or robotic gynecologic surgery requiring observation or inpatient stay overnight~* Agree to receiving contact from research staff for follow up~* Can provide two telephone numbers or a telephone number and email address~Exclusion Criteria:~* Unable to provide informed consent~* Age \<18~* Intolerance/allergy to more than two narcotic medications~* Allergy/contraindication to non-steroidal anti-inflammatory drugs (NSAIDs)~* Has a diagnosed gynecologic malignancy other than Grade 1 endometrial cancer~* Pregnant~* Current opioid use on a regular basis (more than twice per week)~* Illicit drug-use within the past 30 days

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: None

Study Arms:
- Subjects who undergo gynecologic surgery (Type: None): Subjects who will undergo gynecologic surgery via vaginally, laparoscopic , or robotic who require observation or inpatient stay overnight. This group will receive pain medication in the hospital and will also be discharged home with pain medication.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Study of Pegylated Interferon-Alfa 2b in Combination With PUVA Therapy In CTCL

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Histologically confirmed mycosis fungoides/Sezary syndrome~  * Stage IB-IVA disease~ * Erythrodermic disease allowed~* Measurable disease~  * One or more indicatory lesions must be designated prior to study entry~PATIENT CHARACTERISTICS:~* ECOG/WHO performance status 0-1~* Life expectancy ≥ 3 months~* Absolute neutrophil count ≥ 1,500/mm³~* Platelet count ≥ 75,000/mm³~* WBC ≥ 3,000/mm³~* Serum creatinine ≤ 2.0 mg/dL~* Total serum bilirubin ≤ 2.2 mg/dL~* Serum AST and ALT ≤ 2 times upper limit of normal~* Not pregnant or nursing~* Negative pregnancy test~* Fertile patients must use effective contraception~* Patients must be disease free of prior malignancies for ≥ 5 years except currently treated squamous cell or basal cell carcinoma of the skin, carcinoma in situ of the cervix, or surgically removed melanoma in situ of the skin (stage 0), with histologically confirmed free margins of excision~* No history of seizure disorder or severe heart disease~* No acute infections~* Diagnosed depression allowed with receiving appropriate care for depression~PRIOR CONCURRENT THERAPY:~* No prior psoralens with ultraviolet light A or interferon alfa therapy~* More than 4 weeks since prior topical therapy, systemic chemotherapy, or biologic therapy~* More than 4 weeks since prior surgery and fully recovered~* At least 1 week since prior antibiotics~* No other concurrent standard or investigational topical and systemic antipsoriatic or anticancer therapies including radiation, steroids, retinoids, nitrogen mustard, thalidomide, or other investigational agents~* No concurrent topical agents except emollients

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 120 Years
- Healthy Volunteers: f

Study Arms:
- PEG-IFN-α-2b + UV therapy (Type: EXPERIMENTAL): Pegylated interferon α-2b in combination with UV therapy (either PUVA or NB-UVB).

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Everolimus Versus Placebo in Head and Neck Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis of Squamous cell carcinoma of the head and neck (stage IVa or IVb). No evidence (absence)of disease by scan.~* 18 years or older.~* Performance status 70% or better.~* Adequate marrow, renal and liver function (will be tested by labs). _ Able give consent.~Exclusion Criteria:~* Currently receiving anti-cancer treatment.~* Major surgery or traumatic injury within 4 weeks.~* Radiotherapy related toxicities.~* Lip, nasopharynx, nasal cavity, paranasal sinus, salivary gland, skin, or thyroid primary tumors~* Receiving other investigational drugs.~* Receiving chronic, systemic treatment with corticosteroids or another immunosuppressive agent.~* Receive immunization with attenuated live vaccines (seasonal flu shot)1 week before starting this .~* Show evidence of disease (cancer).~* Uncontrolled medical conditions such as: unstable angina, congestive heart failure, diabetes, severely impaired lung function.~* Liver disease such as cirrhosis, severe hepatic impairment, Hepatitis B or C.~* Active, uncontrolled severe infections~* Other malignancies within the past 3 years except for adequately treated carcinoma of the cervix or basal or squamous cell carcinomas of the skin.~* Known History of HIV positivity.~* Impaired gastrointestinal function that may alter absorption of Everolimus such as ulcerative disease, uncontrolled nausea, vomiting, diarrhea, malabsorption syndrome or small bowel resection.~* Patients with an active, bleeding diathesis.~* Female patients who are pregnant or breast feeding, or adults of reproductive potential who are not using effective birth control methods. )~* Male patient whose sexual partner(s) are Women of child bearing potential who are not willing to use adequate.~contraception, during the study and for 8 weeks after the end of treatment~* Patients who have received prior treatment with an mTOR inhibitor (sirolimus, temsirolimus, everolimus).~* Patients with a known hypersensitivity to Everolimus or other rapamycin analogues (sirolimus, temsirolimus) or to its excipients.~* History of noncompliance to medical regimens.~* Patients unwilling to or unable to comply with the protocol.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Everolimus (RAD001) (Type: EXPERIMENTAL): Subjects will receive Everolimus 10 mg daily
- Placebo (Type: EXPERIMENTAL): Subjects will receive double-blind placebo

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Radio Frequency (RF) Device for Reduction in Size of Localized Areas of the Body

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Female or Male~* Minimum age of 18 years~* Non-smoking for at least 3 months and willing to refrain from smoking for the duration of the study.~* Post-menopausal, or on birth control with no plans to become pregnant for the duration of the study (female only)~* Minimum Body Mass Index of 20~* Visible fat in the area to be treated Area to be treated to measure at least 20.0mm in vertical fold, as measured with industry standard fat caliper~* Subject must be able to read, understand and sign the Consent Form~* Subject must adhere to the follow-up schedule and study instructions~* Subject must adhere to the same diet and/or exercise routine throughout the study, and agree to maintain the same weight throughout the study (within 6 lbs of initial weight)~Exclusion Criteria:~* Significant weight fluctuation (+/-10 lbs) in the past 6 months~* Taking weight-loss medications/supplements~* Participation in any other clinical study~* Cellulite treatment within 3 months of the treatment~* Surgical or non-surgical treatments to the target area in the last 12 months, e.g., liposuction~* Prior treatment to the target area within the last 12 months~* Arteriosclerosis or weakened blood vessels~* Heart disease~* Thromboembolic disease~* Diagnosed or documented immune system disorders~* Bleeding disorders.~* Presence of uncontrolled hypertension~* Taking prescription anticoagulants~* History of keloid formation~* Malignant tumors in the target area~* Diabetes~* Any disease or condition that could impair wound healing~* Skin abnormalities in the target area, e.g., cuts, scrapes, wounds, scars, large moles~* Infection in the target area~* Implanted electrical device(s)~* Pregnant or lactating

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 55 Years
- Healthy Volunteers: f

Study Arms:
- RF treatment (Type: EXPERIMENTAL): Abdomen, flank or thigh treated with RF device

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Transcranial Magnetic Stimulation (TMS) for Primary Progressive Apraxia of Speech (PPAOS)

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Adults ages 18 and above who are able to consent~* Diagnosis of primary progressive apraxia of speech based on neurological evaluation~Exclusion Criteria:~* Any uncontrolled medical condition expected to limit life expectancy or interfere with participation in the trial (i.e. unstable cancer, severe depression or anxiety by DSM-IV criteria)~* Abnormal stress test, as determined by the treating physician (unless cardiology clearance provided)~* Active substance abuse or alcohol dependence~* Uncorrected vision or hearing deficits that would preclude administration of the cognitive measures~* Unwilling or unable to provide written informed consent~* History of fainting spells of unknown or undetermined etiology that might constitute seizures~* History of seizures, diagnosis of epilepsy, history of abnormal (epileptiform) EEG or family history of treatment resistant epilepsy~* No medication is an absolute exclusion from TMS. Medications will be reviewed by the responsible MD and a decision about inclusion will be made based on the following:~  * The subject's past medical history, drug dose, history of recent medication changes or duration of treatment, and combination with other CNS active drugs.~ * The published TMS guidelines review medications to be considered with TMS~* Any metal in the brain, skull or elsewhere unless approved by the responsible MD~* Any medical devices (i.e. Cardiac pacemaker, deep brain stimulator, medication infusion pump, cochlear implant, vagal nerve stimulator) unless otherwise approved by the responsible MD~* Substance abuse or dependence within the past six months~* Absence of corticospinal functional integrity

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Transcranial Magnetic Stimulation (TMS) (Type: EXPERIMENTAL): Non-invasive brain stimulation, high frequency repetitive TMS delivered in 10 sessions over a 2-week period.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Different Schemes of Magnesium Sulfate for Preeclampsia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Severe Preeclampsia (pure and superimposed)~Exclusion Criteria:~* Eclampsia before administration of the loading dose of MgSO4 ;~* Use of other medications or illicit drugs that may interfere with maternal hemodynamics;~* Contraindications to the use of magnesium sulfate: known hypersensitivity to the drug, oliguria with urine output below 25 ml per hour or anuria (urine output absent) and myasthenia gravis.~* Use of mechanical ventilation

- Gender: FEMALE
- Minimum Age: 14 Years
- Maximum Age: 50 Years
- Healthy Volunteers: f

Study Arms:
- Magnesium sulfate 50% - 1g/h (Type: ACTIVE_COMPARATOR): After loading dose of 6g of magnesium sulfate, patients will receive the maintenance dose of 1g/hour of intravenous magnesium sulfate, for 24 hours
- Magnesium sulfate 50% - 2g/h (Type: EXPERIMENTAL): After loading dose of 6g of magnesium sulfate, patients will receive the maintenance dose of 2g/hour of intravenous magnesium sulfate, for 24 hours

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Besifloxacin Ophthalmic Suspension Verses Gatifloxacin Ophthalmic Solution in Neonates With Bacterial Conjunctivitis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Subjects who have a clinical diagnosis of acute bacterial conjunctivitis and exhibit conjunctival discharge and redness in at least one eye. A minimum score of 1 should be present for discharge and a minimum score of 1 for conjunctival hyperemia in the same eye.~Exclusion Criteria:~* Subjects with conjunctivitis signs and/or symptoms suggestive of fungal, protozoal, or viral etiology in either eye.~* Subjects who require or are expected to require (other than study medication) use of any topical ocular medication in either eye, or systemic medications during the course of the study or prior to Day 1 specified in the protocol as ineligible.~* Subjects with any abnormality of the ocular anatomy or ocular disease/disorder specified in the protocol as ineligible.~* Subjects with systemic disease/disorder specified in the protocol as ineligible.~* Subjects who have a known or suspected poor tolerance, sensitivity, or allergy to the study medications or any of their components.~* Subjects who have a condition or are in a situation which in the investigator's opinion may impact their safety or would negatively affect the conduct or outcome of the study.

- Gender: ALL
- Minimum Age: 1 Day
- Maximum Age: 31 Days
- Healthy Volunteers: f

Study Arms:
- Besivance (Type: EXPERIMENTAL): Besifloxacin 0.6% ophthalmic suspension
- Gatifloxacin (Type: ACTIVE_COMPARATOR): Gatifloxacin 0.3% ophthalmic solution

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues